[Carbapenem resistance and Acinetobacter baumannii].
Oliver
Antonio
A
D000151:Acinetobacter Infections / Q000188:drug therapy / Q000453:epidemiology / Q000382:microbiology*; D040981:Acinetobacter baumannii / Q000187:drug effects* / Q000201:enzymology / Q000235:genetics / Q000302:isolation & purification; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001426:Bacterial Proteins / Q000235:genetics / Q000502:physiology; D015780:Carbapenems / Q000494:pharmacology*; D003428:Cross Infection / Q000188:drug therapy / Q000453:epidemiology / Q000382:microbiology; D004196:Disease Outbreaks; D024881:Drug Resistance, Bacterial / Q000235:genetics / Q000502:physiology; D024901:Drug Resistance, Multiple, Bacterial / Q000235:genetics / Q000502:physiology; D006801:Humans; D015337:Multicenter Studies as Topic; D013030:Spain / Q000453:epidemiology; D001618:beta-Lactamases / Q000235:genetics / Q000502:physiology
D000900:Anti-Bacterial Agents; D001426:Bacterial Proteins; D015780:Carbapenems; D001618:beta-Lactamases; C063912:carbapenemase